Table 2. Univariate and multivariate analyses of the predictive factors of postoperative relapse and postoperative early relapse in patients with stage III colorectal cancer.
| Parameters | Postoperative Relapse | Postoperative Early Relapse | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariable analysis | Univariate analysis | Multivariable analysis | |||||
| ORd (95% CIe) | p value | ORd (95% CIe) | p value | ORd (95% CIe) | p value | ORd (95% CIe) | p value | |
| Age (years) | ||||||||
| ≥65 vs <65 (80/98) | 0.634 (0.350 –1.149) | 0.133 | 0.657 (0.329 –1.310) | 0.233 | 0.622 (0.278 –1.389) | 0.247 | 0. 117 (0.272 –1.858) | 0.486 |
| Gender | ||||||||
| Male vs Female (108/70) | 1.099 (0.602 –2.005) | 0.759 | 0.817 (0.394 –1.697) | 0.589 | 1.219 (0.544 –2.730) | 0.63 | 0.807 (0.291 –1.697) | 0.681 |
| Location | ||||||||
| Colon vs Rectum (147/31) | 0.574 (0.260 –1.267) | 0.17 | 0.489 (0.189 –1.267) | 0.141 | 0.406 (0.259 –1.728) | 0.406 | 0.344 (0.101 –1.165) | 0.086 |
| Tumor size | ||||||||
| ≥5 cm vs <5 cm (66/111) | 1.192 (0.647 –2.194) | 0.573 | 1.001 (0.471 –2.129) | 0.998 | 1.746 (0.799 –3.818) | 0.162 | 1.641 (0.595 –4.525) | 0.338 |
| Tumor depth | ||||||||
| T3 + T4 vs T1 + T2 (158/20) | 2.004 (0.759 –5.288) | 0.16 | 1.364 (0.414 –4.492) | 0.609 | 1.221 (0.335 –4.450) | 0.763 | 1.158 (0.224 –5.986) | 0.861 |
| Lymph Node metastasis | ||||||||
| N2 vs N1 (57/121) | 1.596 (0.845 –3.014) | 0.15 | 1.121 (0.514 –2.441) | 0.774 | 1.992 (0.903 –4.396) | 0.088 | 1.656 (0.594 –4.619) | 0.335 |
| Histology | ||||||||
| PD vs MD+WDb (22/155) | 1.247 (0.509 –3.057) | 0.629 | 1.051 (0.363 –3.043) | 0.926 | 0.685 (0.232 –2.023) | 0.494 | 1.737 (0.463 –6.514) | 0.413 |
| Vascular invasion | ||||||||
| Yes vs No (57/120) | 0.842 (0.448 –1.583) | 0.593 | 0.872 (0.407 –1.872) | 0.725 | 0.689 (0.287 –1.651) | 0.403 | 0.358 (0.109 –1.171) | 0.089 |
| Perineurial invasion | ||||||||
| Yes vs No (62/115) | 1.325 (0.713 –2.462) | 0.374 | 0.948 (0.445 –2.019) | 0.889 | 0.861 (0.377 –1.966) | 0.722 | 0.558 (0.184 –1.689) | 0.302 |
| Pre-op CEAc (ng/ml) | ||||||||
| ≥5/ vs <5 (78/93) | 1.480 (0.808 –2.709) | 0.204 | 1.186 (0.568 –2.476) | 0.649 | 1.344 (0.604 –2.990) | 0.469 | 0.476 (0.153 –1.482) | 0.2 |
| Post-op CEAc (ng/ml) | ||||||||
| ≥5 vs <5 (30/145) | 2.872 (1.232 –6.697) | 0.015 | 2.861 (1.031 –7.938) | 0.043 | 4.704 (1.948 –11.358) | 0.001 | 8.524 (2.504 –29.018) | 0.001 |
| EGFR expression | ||||||||
| Positive vs Negative (108/65) | 3.424 (1.789 –6.552) | < 0.001 | 3.106 (1.512 –6.379) | 0.002 | 2.962 (1.144 –7.670) | 0.025 | 2.572 (0.875 –7.559) | 0.086 |
aAJCC: American Joint Commission on Cancer; bPD: poorly differentiated, MD: moderately differentiated, WD: well differentiated; cCEA: carcinoembryonic antigen; dOR: odd ratio; eCI: confidence interval, *p < 0.05.